Boston hub
The Monash University Boston Hub exists to make collaborating with Monash simple.
We connect North American and European biotech, pharmaceutical, medtech and investment partners with the right researchers, clinicians and innovation capabilities that help ideas move more efficiently from discovery to real-world impact.
Whether you're looking to conduct clinical trials in Australia, identify research collaborators, explore commercialisation opportunities, evaluate emerging technologies or connect with Monash expertise, our team can help.
How we can collaborate
Clinical trials
Connect with Monash clinical trial networks for the design and delivery of translational and commercially focused clinical trials at any stage.
Sponsored research
Partner with Monash to advance targeted research programmes aligned to your scientific and strategic priorities.
Licensing
Access innovative Monash technologies and intellectual property that has potential for therapeutic, diagnostic and commercial development.
Strategic collaborations
Build long-term partnerships with Monash research, clinical translation and innovation initiatives.
Spinout/investment opportunities
Explore emerging ventures and investment opportunities from Monash’s research and commercialisation ecosystem.
And more
Have another idea for collaboration? We’d love to hear it. Contact us to discuss opportunities today!
Explore some of our recent spinouts
Meet our researchers
Get to know some of our world-leading researchers generating breakthrough science and translating discovery into global therapeutic impact.
Professor Christopher Porter
Professor Christopher Porter is a Sir John Monash Distinguished Professor whose pioneering work has transformed how challenging medicines are designed and delivered. Professor Porter co-developed the Glyph™ platform – a breakthrough drug delivery technology that improves the oral bioavailability and tolerability of neuropsychiatric medicines. Glyph™ has been commercialised through partnerships in the Boston biotech ecosystem and underpins the formation of Seaport Therapeutics, a Boston-based clinical-stage biotechnology company advancing next-generation antidepressant and anxiolytic therapies.
Professor Stephen Nicholls
Professor Stephen Nicholls is Director of the Victorian Heart Institute and the Victorian Heart Hospital, where he leads internationally recognised cardiovascular research integrated with large-scale clinical translation. He has led large-scale international clinical trials that have directly informed global treatment guidelines and accelerated the development of new cardiovascular medicines. Through deep collaboration with pharmaceutical and biotech partners, Professor Nicholls’ work exemplifies Monash’s model of global clinical engagement and therapeutic commercialisation.
